403 results about "Plasma sample" patented technology

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

The invention provides a method for simultaneously detecting main components of paeoniflorin, beta ecdysterone, laetrile, mulberroside A, caffeic acid, ferulic acid, salvianolic acid B, astragaloside, formononetin, cryptotanshinone and tanshinone IIA of a Naoxintong capsule in a plasma sample by a liquid chromatography-tandem mass spectrometry (HPLC-MS / MS). In a liquid chromatogram, a mobile phase consists of acetonitrile and a formic acid aqueous solution of which the volume fraction is 0.1%, and gradient elution is used. A mass spectrum uses a quick positive and negative ions switching and analyzing mode and an MRM (Multiple Reaction Monitoring) scanning manner. After the Naoxintong capsule is taken, the situations of the changes of the blood-medicine concentration of several kinds of main components in the plasma of a rat are detected at the same time. The methodological survey results indicate that the established method conforms to determination requirements on biological samples in a body; the method is good in sensitivity, high in specificity, stable, reliable, and suitable for detecting substances with lower contents.

The present invention relates to biomarker combinations, kits for detecting them, and their use in microsatellite instability (MSI) detection and cancer, preferably colorectal cancer (e.g., bowel cancer), gastric cancer or endometrial cancer, prognostic assessment, treatment regimen selection or genetic screening in plasma samples. A method for detecting plasma MSI is provided for the first time,which enables a microsatellite (MS) state of a sample to be judged with high accuracy and sensitivity.

The invention relates to a fluorescent PCR detection kit for the IDH1 / IDH2 (isocitrate dehydrogenase 1 / isocitrate dehydrogenase 2) gene mutation and application thereof, and particularly provides a nucleotide sequence used for detecting the IDH1 / IDH2 gene mutation, a kit with the nucleotide sequence and the application of the kit to detection of the IDH1 / IDH2 gene mutation. The nucleotide sequence comprises a specific ARMS (Amplification Refractory Mutation System) primer, a general mutation detection TaqMan probe and a nucleic acid amplification retardation primer. The kit can be used for quickly detecting the IDH1 / IDH2 gene mutation with high throughput and at a low cost, is high in sensitivity, good in specificity, low in pollution and quick and safe to operate, can be suitable for high-sensitivity detection of trace mutation in general clinic samples such as fresh frozen tissues and paraffin tissues, especially non-traumatic serums or plasma samples in addition to pathological tissues.

A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and / or anticoagulated plasma samples, and an equipment kit are described.

The invention relates to a method of detecting chromosomal abnormalities, in particular, the invention relates to the diagnosis of fetal chromosomal abnormalities such as trisomy 21 (Down's syndrome) which comprises sequence analysis of cell-free DNA molecules in plasma samples obtained from maternal blood during gestation of the fetus.

The invention relates to new application of small molecular metabolites caffeine, creatinine, eicosamide, phenylacetylglutamine, decanoic acid and indolelactic acid in a plasma sample as combined markers in preparation of a kit for diagnosing Parkinson's disease patients in subjects. The invention also relates to the kit for detecting the Parkinson's disease patients in the subjects, and the kit is used for calculating the variables of the combined markers based on a binary logistic regression equation by detecting the respective relative concentrations of the combined markers in the plasma from the subjects, and judging whether the subjects suffer from Parkinson's disease or not based on determined intercept values. The kit can realize high-sensitivity detection of several metabolites involved in the invention, and has the characteristics of low detection cost and good repeatability. The combined use of the small molecule metabolites can be used for assisting the clinical diagnosis ofthe Parkinson's disease, and has higher development and application values.

The invention belongs to the technical field of clinical medical diagnosis and relates to a screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis. The screening method of the early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis liver cirrhosis and hepatitis comprises the following steps of: S1, acquiring data, specifically, collecting a target plasma sample and detecting metabolites in the plasma sample; S2, constructing a discrimination model used for distinguishing people with liver cirrhosis from patients with the primary liver cancer and distinguishing people with the hepatitis from patients with the primary liver cancer; S3, screening markers; and S4, verifying diagnosis capability. According to the screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis, a high performance liquid chromatography-mass spectrometry system is utilized to obtain the metabolic profiles of blood plasma of patients with liver cirrhosis, hepatitis and hepatocellular carcinoma, a potential tumor metabolic marker group is found, and a diagnosis model is constructed and is used for assisting early diagnosis of tumors of groups with high risk of liver cancer.